Trials / Completed
CompletedNCT00602173
Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions
A Single Dose, Randomized, Three-Period, Three-Treatment, Crossover Bioequivalency Study of Cilostazol 100 mg Tablets Under Fasting Conditions
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Roxane Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 100 mg, to PLETAL® Tablets, 100 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 3-treatment, 3-period, crossover design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilostazol |
Timeline
- Start date
- 2003-05-01
- Primary completion
- 2003-05-01
- Completion
- 2003-05-01
- First posted
- 2008-01-28
- Last updated
- 2018-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00602173. Inclusion in this directory is not an endorsement.